Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

Next Previous
Trial Profile

A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alprazolam (Primary)
  • Indications Epilepsy; Generalised epilepsy; Generalised seizures; Partial epilepsies
  • Focus Therapeutic Use
  • Acronyms StATES
  • Sponsors Engage Therapeutics

Most Recent Events

  • 12 Oct 2022 Results of Phase 2b study assessing the efficacy of alprazolam for rapid seizure termination in patients with seizure episodes with a predictable pattern published in the Epilepsia
  • 08 Dec 2020 Results from part 2 portion of this phase 2b assessing efficacy, feasibility and safety of STAP treatment in patients with predictable seizure patterns presented at the 74th Annual Meeting of the American Epilepsy Society
  • 01 May 2020 Topline Results from Part 2 (data cut off: 4 October 2019; n=74) presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top